1. Home
  2. STRO vs AIP Comparison

STRO vs AIP Comparison

Compare STRO & AIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STRO
  • AIP
  • Stock Information
  • Founded
  • STRO 2003
  • AIP 2003
  • Country
  • STRO United States
  • AIP United States
  • Employees
  • STRO N/A
  • AIP N/A
  • Industry
  • STRO Biotechnology: Biological Products (No Diagnostic Substances)
  • AIP Semiconductors
  • Sector
  • STRO Health Care
  • AIP Technology
  • Exchange
  • STRO Nasdaq
  • AIP Nasdaq
  • Market Cap
  • STRO 292.6M
  • AIP 277.9M
  • IPO Year
  • STRO 2018
  • AIP 2021
  • Fundamental
  • Price
  • STRO $2.81
  • AIP $8.81
  • Analyst Decision
  • STRO Strong Buy
  • AIP Strong Buy
  • Analyst Count
  • STRO 7
  • AIP 4
  • Target Price
  • STRO $12.14
  • AIP $13.00
  • AVG Volume (30 Days)
  • STRO 1.0M
  • AIP 155.7K
  • Earning Date
  • STRO 11-13-2024
  • AIP 11-05-2024
  • Dividend Yield
  • STRO N/A
  • AIP N/A
  • EPS Growth
  • STRO N/A
  • AIP N/A
  • EPS
  • STRO N/A
  • AIP N/A
  • Revenue
  • STRO $160,955,000.00
  • AIP $54,739,000.00
  • Revenue This Year
  • STRO N/A
  • AIP $8.13
  • Revenue Next Year
  • STRO N/A
  • AIP $19.08
  • P/E Ratio
  • STRO N/A
  • AIP N/A
  • Revenue Growth
  • STRO 230.90
  • AIP 4.53
  • 52 Week Low
  • STRO $2.45
  • AIP $4.83
  • 52 Week High
  • STRO $6.13
  • AIP $9.54
  • Technical
  • Relative Strength Index (RSI)
  • STRO 40.82
  • AIP 59.09
  • Support Level
  • STRO $2.66
  • AIP $8.28
  • Resistance Level
  • STRO $2.86
  • AIP $9.31
  • Average True Range (ATR)
  • STRO 0.17
  • AIP 0.42
  • MACD
  • STRO 0.03
  • AIP 0.02
  • Stochastic Oscillator
  • STRO 64.29
  • AIP 67.74

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

About AIP Arteris Inc.

Arteris Inc is a developer of on-chip interconnect fabric technology designed for a variety of devices and in the development and distribution of Network-on-Chip (NoC) interconnect intellectual property (IP). The company's technology is used in System-on-Chip (SoC) and provides software and services to automate SoC integration, enabling users to efficiently deploy NoC IP, and offer IP support, maintenance services, professional services, and training and on-site support services. The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.

Share on Social Networks: